In a non-pregnant patient with type 2 diabetes, a GLP-1 agonist or SGLT2 inhibitor can be prescribed if adequate glycemic control is not achieved with metformin, sulphonylureas or (basal) insulin, or if weight reduction, hypoglycemia prevention or reduction of cardiovascular risk is the treatment goal (8–10). Here, SLC5A2 is linked to type 2 diabetes mellitus.